"The United States pays undeniably high prices for brand-name drugs, but when it comes to generics, the country gets a very good deal. Americans pay less, on average, for generic medications than people in any other peer nation."
"The case Hikma v. Amarin pits the generic drugmaker Hikma against Amarin, the maker of Vascepa, a brand-name drug made from purified fish oil for people at high risk of heart disease."
"Skinny labeling allows companies to begin selling their cheaper version of the medicine just for those unpatented uses, helping to avoid expensive patent litigation and deliver lower prices for patients and insurers sooner."
"One study found that, by shepherding low-cost competition to market sooner, skinny labeling saved Medicare nearly $15 billion between 2015 and 2021."
Americans pay less for generic medications than any other peer nation, but brand-name monopolies can delay access to these savings. The Supreme Court case Hikma v. Amarin involves a dispute over 'skinny labeling,' which allows generic drugmakers to market cheaper versions of medications for unpatented uses. This strategy has enabled over two dozen generic drugs to enter the market, saving Medicare nearly $15 billion from 2015 to 2021. The case centers on Amarin's patent for Vascepa and Hikma's subsequent skinny label approval for its generic version.
Read at www.npr.org
Unable to calculate read time
Collection
[
|
...
]